Long-term safety and efficacy of the recombinant human growth hormone omnitrope® in the treatment of Spanish growth hormone deficient children: Results of a phase III study-Reference-Cited by-同舟云学术

Long-term safety and efficacy of the recombinant human growth hormone omnitrope® in the treatment of Spanish growth hormone deficient children: Results of a phase III study

Published:2011-09-20 Issue:10 Volume:28 Page:879-893
ISSN:0741-238X
Container-title:Advances in Therapy
language:en
Short-container-title:Adv Therapy

Author:

López-Siguero J.,Borrás Pérez V.,Balser S.,Khan-Boluki J.

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),General Medicine

Link

http://link.springer.com/content/pdf/10.1007/s12325-011-0063-8.pdf

Reference38 articles.

1. Child Growth Foundation. Endocrine Gland Disorders. Available at: http://www.childgrowthfoundation.org/ghd.htm . Accessed June 20, 2011.

2. NICE Technology Appraisal 2010; human growth hormone (somatropin) for the treatment of growth failure in children. Available at: http://www.nice.org.uk/nicemedia/live/12992/48715/48715.pdf Accessed August 15, 2011.

3. Lindsay R, Feldkamp M, Harris D, et al. Utah Growth Study: growth standards and the prevalence of growth hormone deficiency. J Pediatr. 1994;125:29–35.

4. Strobl JS, Thomas, MJ. Human growth hormone. Pharmacol Rev. 1994;46:1–34.

5. Pavlovic M, Girardin E, Kapetanovic L, et al. Similar biological medicinal products containing recombinant human growth hormone: European regulation. Horm Res. 2008;69:14–21.

Cited by 21 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Safety and Effectiveness of a Biosimilar Recombinant Human Growth Hormone in Children Requiring Growth Hormone Treatment: Analysis of Final Data from PATRO Children, an International, Post-Marketing Surveillance Study;Drug Design, Development and Therapy;2024-03

2. Pharmacokinetics and pharmacodynamics of once-weekly administration of JR-142, a long-acting albumin-fused human growth hormone: A rondemized, placebo-controlled phase 1 study;Growth Hormone & IGF Research;2022-12

3. Metabolomic Differential Compounds Reflecting the Clinical Efficacy of Polyethylene Glycol Recombinant Human Growth Hormone in the Treatment of Childhood Growth Hormone Deficiency;Frontiers in Pharmacology;2022-04-27

4. Safety and effectiveness of a somatropin biosimilar in children requiring growth hormone treatment: second analysis of the PATRO Children study Italian cohort;Journal of Endocrinological Investigation;2020-06-15

5. Ten years with biosimilar rhGH in clinical practice in Sweden – experience from the prospective PATRO children and adult studies;BMC Endocrine Disorders;2020-04-29